Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275157 · ClinicalTrials.gov registry record · Phase 1
Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01275157 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants.
The verdict
NCT01275157, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single dose study of radiolabeled \[14C\]-LY2452473 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY2452473. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG LY2452473
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275157
The ClinicalTrials.gov registry entry for NCT01275157 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2452473 is the first listed.
NCT01275157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275157 about?
NCT01275157 is a clinical study titled "Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects". This is a single dose study of radiolabeled \[14C\]-LY2452473 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY2452473. This study is for research purposes only and is not intended to treat any medical condition.
What is the current status of trial NCT01275157?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01275157?
The interventions under investigation include: LY2452473 (DRUG).
Who is sponsoring clinical trial NCT01275157?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.